Adaptate Biotherapeutics has discovered a unique range of antibodies that selectively modulate targets on gamma delta T cells.

These antibodies provide a precisely targeted signal to the patient’s gamma delta T cells.

In Oncology, our solid tumour approaches are designed to modulate tumour-infiltrating gamma delta T cells to augment their cytotoxicity and disrupt the tumour microenvironment. Our unprecedented approach thereby sets new standards in immunomodulation through the exquisite targeting of this most desired class of effector cells.

Talk to US

This form collects your name and email to enable us to contact you regarding your enquiry. For further information on how we protect and manage your submitted data view our privacy policy.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.